LPL Financial LLC Has $2.33 Million Holdings in Repligen Co. (NASDAQ:RGEN)

LPL Financial LLC cut its position in shares of Repligen Co. (NASDAQ:RGEN – Get Rating) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,159 shares of the biotechnology company’s stock after selling 80 shares during the quarter. LPL Financial LLC’s holdings in Repligen were worth $2,330,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Repligen by 0.5% during the third quarter. Vanguard Group Inc. now owns 5,128,884 shares of the biotechnology company’s stock worth $959,665,000 after purchasing an additional 24,998 shares during the period. Invesco Ltd. grew its stake in Repligen by 3.9% during the first quarter. Invesco Ltd. now owns 1,756,157 shares of the biotechnology company’s stock worth $330,315,000 after purchasing an additional 65,550 shares during the period. Sands Capital Management LLC acquired a new stake in Repligen in the third quarter worth $306,666,000. WCM Investment Management LLC grew its holdings in Repligen by 5.4% in the fourth quarter. WCM Investment Management LLC now owns 1,601,982 shares of the biotechnology company’s stock worth $271,232,000 after purchasing an additional 82,356 shares during the period. Finally, State Street Corp grew its holdings in Repligen by 1.3% in the third quarter. State Street Corp now owns 1,393,580 shares of the biotechnology company’s stock worth $260,753,000 after purchasing an additional 18,369 shares during the period. Institutional investors and hedge funds own 91.00% of the company’s stock.

Repligen Stock Up 1.7 %

Repligen stock opened at $159.25 on Monday. Repligen Co. has a 52 week low of $137.65 and a 52 week high of $262.26. The stock has a market cap of $8.87 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 2.76 and a beta of 1.08. The business has a 50-day simple moving average of $163.39 and a 200 day simple moving average of $173.11.

Repligen (NASDAQ:RGEN – Get Rating) last announced its quarterly earnings data on Tuesday, May 2nd. The biotechnology company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. Repligen had a net margin of 21.58% and a return on equity of 9.14%. The company had revenue of $182.70 million during the quarter, compared to analysts’ expectations of $181.43 million. During the same quarter in the prior year, the company earned $0.92 EPS. The firm’s revenue was down 11.5% on a year-over-year basis. On average, research analysts anticipate that Repligen Co. will post 2.37 earnings per share for the current year.

Insider Buying and Selling

In other Repligen news, Director Martin D. Madaus bought 500 shares of the firm’s stock in a transaction on Monday, May 8th. The stock was acquired at an average price of $156.18 per share, with a total value of $78,090.00. Following the completion of the purchase, the director now owns 1,611 shares of the company’s stock, valued at $251,605.98. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 1.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of research reports. StockNews.com initiated coverage on shares of Repligen in a report on Thursday. They issued a “sell” rating for the company. Craig Hallum reduced their price objective on Repligen from $220.00 to $207.00 in a research note on Wednesday, May 3rd. Stifel Nicolaus reduced their price objective on Repligen from $225.00 to $210.00 in a research note on Wednesday, May 3rd. Deutsche Bank Aktiengesellschaft reduced their price objective on Repligen from $180.00 to $165.00 in a research note on Wednesday, May 3rd. Finally, TheStreet downgraded shares of Repligen from a “b-” rating to a “c+” rating in a research report on Monday, May 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and a consensus price target of $208.56.

Repligen Profile

(Get Rating)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.